Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 5/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298159 | 0.85 | CA1 (0.35) | CA1CA2CA4CA6PGR | |
| SCHEMBL2292309 | 0.76 | MAOA (0.47) | MAOACA1CA2CA4CA6 | |
| SCHEMBL12422155 | 0.72 | CA1 (0.52) | MAPK14CA1CA2CA4CA6 | |
| SCHEMBL12382619 | 0.66 | HTR2A (0.37) | KMT2AACHEALDH1A1 | |
| SCHEMBL2295376 | 0.65 | ATM (0.46) | KMT2ACA1CA2CA4CA6 | |
| SCHEMBL2299111 | 0.63 | PARP1 (0.46) | MAOAKMT2ACA1CA2CA4 | |
| SCHEMBL12601836 | 0.61 | HTR5A (0.43) | KMT2AACHEALDH1A1HTTNTRK1 | |
| SCHEMBL17697978 | 0.61 | DRD2 (0.56) | KMT2ACA1CA2CA4CA6 | |
| SCHEMBL2296035 | 0.61 | CA1 (0.53) | MAOAKMT2ACA1CA2CA4 | |
| SCHEMBL7169702 | 0.61 | METAP1 (0.51) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519122-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | PTMS, APEX1, ALG1 | MAOA 1070/4885WDR5 3985/4885MAPK14 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.